Nadofaragene firadenovec
Published 11th January 2019, updated 9th March 2019
Unassigned
New Medicines
Adstiladrin · High-grade non-muscle invasive bladder cancer (NMIBC) in patients who are BCG unresponsive
Information
Adstiladrin
Advanced therapy medicinal product (ATMP)
Ferring
Ferring
Development and Regulatory status
None
None
Phase III Clinical Trials
Category
A non-replicating adenovirus vector harboring the human IFN alpha2b gene. When combined with the excipient Syn3, intravesical administration of the rAd-IFN results in transduction of the virus into the epithelial cell lining in the bladder.
The overall incidence of bladder cancer in the UK is 11.4 per 100,000 population. At diagnosis, only about 5% of patients have metastatic disease, usually to lymph nodes, lung, liver, bone and central nervous system. Around 30% have involvement of the muscle layer. Around 70% have superficial disease, of which 10% is CIS [1]. ·
High-grade non-muscle invasive bladder cancer (NMIBC) in patients who are BCG unresponsive
Intravesical
Evidence based evaluations
NIHR ·